November 26, 2024
Collaboration achieves significant health gains for high-risk participants in type 2 diabetes program
October 16, 2024
Indigenous communities and partners unite to bridge gaps in healthcare through PATHWAYS initiative
October 11, 2024
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
September 16, 2024
University of Saskatchewan’s Dr. Diego Moya named 2024 Metacam® Bovine Welfare Award winner
September 16, 2024
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study
July 23, 2024
Boehringer Ingelheim Canada’s national program is helping people living with diabetes and heart failure by addressing health system gaps
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 18, 2024
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
June 07, 2024
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
May 07, 2024
Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
March 13, 2024
Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet
December 07, 2023
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
November 21, 2023
Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
October 25, 2023
Breathing new life into patient care: Innovative partnership aims to transform interstitial lung disease support
October 11, 2023
Digital Clinical Support Tool Aims to Individualize Guidelines-Based Diabetes Care
September 27, 2023
University of Guelph’s Dr. Charlotte Winder named 2023 Metacam® 20 Bovine Welfare Award winner
August 01, 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
June 15, 2023
Boehringer Ingelheim Animal Health launches the first vaccine combination to protect pigs in Canada against two devastating diseases in one shot
March 29, 2023
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
March 23, 2023
Health Canada approves first treatment option for generalized pustular psoriasis flares in adults
February 07, 2023
Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba
January 25, 2023
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
January 20, 2023
Alberta’s Dr. Calvin Booker named bovine veterinarian of the year by the Western Canadian Association of Bovine Practitioners
January 01, 2023
Philanthropic partnership sets sights on sustainable improvements to health care
December 23, 2022
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
November 29, 2022
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
November 04, 2022
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease
October 13, 2022
Alberta’s Dr. Karen Schwartzkopf-Genswein named 2022 Metacam® 20 Bovine Welfare Award winner
October 05, 2022
Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV
September 28, 2022
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
August 03, 2022
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
May 15, 2022
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
April 19, 2022
New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec
April 12, 2022
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction
April 06, 2022
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
March 28, 2022
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
February 15, 2022
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
November 18, 2021
World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program
November 03, 2021
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
November 03, 2021
Boehringer Ingelheim increases commitments to sustainable development
November 01, 2021
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Media contacts
Communications, Media & Public Relations
Director, Communications
Phone (905) 631-4713
Mobile (905) 599-2364
Communications, Media & Public Relations
Corporate Communications
Phone (905) 631-4531
Mobile (647) 637-8265
